Analysts See $-0.03 EPS for Co-Diagnostics, Inc. (CODX)

Analysts expect Co-Diagnostics, Inc. (NASDAQ:CODX) to report $-0.03 EPS on August, 21.After having $-0.09 EPS previously, Co-Diagnostics, Inc.’s analysts see -66.67 % EPS growth. The stock decreased 8.20% or $0.1 during the last trading session, reaching $1.12. About 133,382 shares traded. Co-Diagnostics, Inc. (NASDAQ:CODX) has declined 63.11% since August 16, 2018 and is downtrending. It has underperformed by 63.11% the S&P500.

Co-Diagnostics, Inc. (NASDAQ:CODX) Ratings Coverage

Among 2 analysts covering Co-Diagnostics (NASDAQ:CODX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Co-Diagnostics has $2 highest and $2 lowest target. $2’s average target is 78.57% above currents $1.12 stock price. Co-Diagnostics had 2 analyst reports since March 11, 2019 according to SRatingsIntel.

Co-Diagnostics, Inc., a molecular diagnostics company, intends to manufacture and sell reagents used for diagnostic tests that function via the detection and/or analysis of nucleic acid molecules. The company has market cap of $19.17 million. It also intends to sell diagnostic equipment from other manufacturers as self-contained lab systems. It currently has negative earnings.

More notable recent Co-Diagnostics, Inc. (NASDAQ:CODX) news were published by: which released: “OSTK, NBIX among premarket gainers – Seeking Alpha” on July 30, 2019, also with their article: “Co-Diagnostics Mosquito Testing Products Generate Buzz – Nasdaq” published on July 23, 2019, published: “Co-Diagnostics, Inc. to Present Products and Services at the 2019 AACC Expo August 4-8 – Nasdaq” on August 01, 2019. More interesting news about Co-Diagnostics, Inc. (NASDAQ:CODX) were released by: and their article: “Co-Diagnostics, Inc. Vector Control Products Continue to Gain Acceptance Across the US – Nasdaq” published on July 30, 2019 as well as‘s news article titled: “A Wild 24 Hours For Co-Diagnostics – Benzinga” with publication date: January 31, 2019.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.